Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Jumps 12% in a Week: But Why?

Northwest Biotherapeutics (OTCMKTS:NWBO) is currently best known for its work related to the development of personal immune therapies meant for solid cancer tumours under the brand DCVax.

Market Stats

On Friday, NWBO stock soared 2.68% at $1.1500 with more than 1.87 million shares, compared to its average volume of 1.46 million shares. The stock has moved within a range of $1.0700 – 1.1900 after opening the trade at $1.0900.

HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

In the past week, the Northwest stock has been on the radars of plenty of investors and managed to clock gains of as much as 12% during the period. Although the gains made by the stock are significant it is also important to keep in mind that in the past week there has been no news about the company that could have led to such gains.

However, back on October 28 the company did announced that it had hit two important milestones which were important for the production of DCVax products at the company’s manufacturing plant located in Sawston in United Kingdom. As a matter of fact, these two key milestones had been in major focus at Northwest ever since the company had been successful in completing the initial construction at Sawston last year.

The company was awarded the license by way of which it could start working with human tissues at the Sawston facility. The license was awarded by the UK Human Tissue Authority. On the other hand, the thorough inspection meant for regulatory needs was also completed by the UK Medicines and Health Products Regulatory Authority.

Traders Corner

NWBO stock is trading below the 20-Day and 50-Day Moving averages of $1.17 and $1.22 respectively. Moreover, the stock is trading below the 200-Day moving average of $1.40. The stock is down 7% in the past 3-month.